Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol.

"Declarations Ethics approval and consent to participateThe study has been approved by the medical ethics review committee of Amsterdam University Medical Centers (METc 2023.0613, protocol version 3 date 16–02-2023). Any future substantial changes to the protocol will undergo review and approval by the medical ethics review committee. This study will be carried out according to the Declaration of Helsinki. The study is registered at ClincialTrials.gov with registration number NCT06068582. Written informed consent for publication of results will be obtained from all participants. Consent for publicationNot applicable. Competing interestsJA, SS, JB, VG, BJ, MK, MR, FS, ES, SV, PW, GW, and KH have nothing to declare with respect to this study.BU has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics.MS serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck.HH is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV. Competing interests JA, SS, JB, VG, BJ, MK, MR, FS, ES, SV, PW, GW, and KH have nothing to declare with respect to this study. BU has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics. MS serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck. HH is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV."

"Funding This project is peer-reviewed and funded by the Dutch Research Council (NOW) as part of the Dutch National Research Agenda (NWA) (file number NWA.1292.19.064). The funder has no influence on the design of the study and data collection, analysis, and interpretation and in writing the manuscript."

"Trial registration Retrospectively registered at ClinicalTrials.gov with reference number NCT06068582 on 10 October 2023."